Association study of CSF2RB with schizophrenia in Irish family and case - Control samples

Molecular Psychiatry

Volumn 13, Issue 10, 2008, Pages 930-938

  Chen, Q ^a   Wang, X ^a   O'Neill, F A ^b   Walsh, D ^c   Fanous, A ^d   Kendler, K S ^a   Chen, X ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c HEALTH RESEARCH BOARD   (Ireland)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Association; Colony stimulating factor; Family history; Interleukin 3; Receptor; Schizophrenia; Sex

Indexed keywords

COLONY STIMULATING FACTOR 2 RECEPTOR BETA; COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 3; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; COLONY STIMULATING FACTOR 2 RECEPTOR BETA GENE; CONTROLLED STUDY; FAMILY; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC MARKER; HAPLOTYPE; HUMAN; IRELAND; MAJOR CLINICAL STUDY; MALE; PEDIGREE ANALYSIS; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CYTOKINE RECEPTOR COMMON BETA SUBUNIT; FAMILY HEALTH; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; IRELAND; LINKAGE DISEQUILIBRIUM; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; SEX FACTORS;

EID: 51949105227     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/sj.mp.4002051     Document Type: Article

References (65)

1. Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet 2003; 73: 34-48.
2. Chen X, Wang X, Hossain S, O'Neill FA, Walsh D, Pless L et al. Haplotypes spanning SPEC2, PDZ-G EF2 and ACSL6 genes are associated with schizophrenia. Hum Mol Genet 2006; 15: 3329-3342.
3. Chen X, Wang X, Hossain S, O'Neill AF, Walsh D, van den Oord EJ et al. Interleukin 3 and schizophrenia: the impact of sex and family history. Mol Psychiatry 2007; 12: 273-282.
4. Gaughran F. Immunity and schizophrenia: autoimmunity, cytokines, and immune responses. Int Rev Neurobiol 2002; 52: 275-302.
5. Jones AL, Mowry BJ, Pender MP, Greer JM. Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis? Immunol Cell Biol 2005; 83: 9-17.
6. Kipnis J, Cardon M, Strous RD, Schwartz M. Loss of autoimmune T cells correlates with brain diseases: possible implications for schizophrenia? Trends Mol Med 2006; 12: 107-112.
7. Bessler H, Levental Z, Karp L, Modai I, Djaldetti M, Weizman A. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol Psychiatry 1995; 38: 297-302.
8. Cazzullo CL, Sacchetti E, Galluzzo A, Panariello A, Colombo F, Zagliani A et al. Cytokine profiles in drug-naive schizophrenic patients. Schizophr Res 2001; 47: 293-298.
9. Rapaport MH, Delrahim KK. An abbreviated review of immune abnormalities in schizophrenia. CNS Spectr 2001; 6: 392-397.
10. Chiavetto LB, Boin F, Zanardini R, Popoli M, Michelato A, Bignotti S et al. Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. Biol Psychiatry 2002; 51: 480-484.
11. He G, Zhang J, Li XW, Chen WY, Pan YX, Yang FP et al. Interleukin-10-1082 promoter polymorphism is associated with schizophrenia in a Han Chinese sib-pair study. Neurosci Lett 2006; 394: 1-4.
12. Zanardini R, Bocchio-Chiavetto L, Scassellati C, Bonvicini C, Tura GB, Rossi G et al. Association between IL-1beta -511C/T and IL-1RA (86 bp)n repeats polymorphisms and schizophrenia. J Psychiatr Res 2003; 37: 457-462.
13. Yu L, Yang MS, Zhao J, Shi YY, Zhao XZ, Yang JD et al. An association between polymorphisms of the interleukin-10 gene promoter and schizophrenia in the Chinese population. Schizophr Res 2004; 71: 179-183.
14. Zhang XY, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 2002; 57: 247-258.
15. Theodoropoulou S, Spanakos G, Baxevanis CN, Economou M, Gritzapis AD, Papamichail MP et al. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr Res 2001; 47: 13-25.
16. Burdach S, Nishinakamura R, Dirksen U, Murray R. The physiologic role of interleukin-3, interleukin-5, granulocytemacrophage colony-stimulating factor, and the beta c receptor system. Curr Opin Hematol 1998; 5: 177-180.
17. Reddy EP, Korapati A, Chaturvedi P, Rane S. IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled. Oncogene 2000; 19: 2532-2547.
18. Chavany C, Vicario-Abejon C, Miller G, Jendoubi M. Transgenic mice for interleukin 3 develop motor neuron degeneration associated with autoimmune reaction against spinal cord motor neurons. Proc Natl Acad Sci USA 1998; 95: 11354-11359.
19. Giralt M, Carrasco J, Penkowa M, Morcillo MA, Santamaria J, Campbell IL et al. Astrocyte-targeted expression of interleukin-3 and interferon-alpha causes region-specific changes in metallothionein expression in the brain. Exp Neurol 2001; 168: 334-346.
20. Sugita Y, Zhao B, Shankar P, Dunbar CE, Doren S, Young HA et al. CNS interleukin-3 (IL-3) expression and neurological syndrome in antisense-IL-3 transgenic mice. J Neuropathol Exp Neurol 1999; 58: 480-488.
21. Powell HC, Garrett RS, Brett FM, Chiang CS, Chen E, Masliah E et al. Response of glia, mast cells and the blood brain barrier, in transgenic mice expressing interleukin-3 in astrocytes, an experimental model for CNS demyelination. Brain Pathol 1999; 9: 219-235.
22. Hanson DR, Gottesman II. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med Genet 2005; 6: 7-24.
23. Sirota P, Schild K, Elizur A, Djaldetti M, Fishman P. Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 75-83.
24. Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane CR et al. Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry 2007; 12: 572-580.
25. Tavernier J, Devos R, Cornelis S, Tuypens T, Van der HJ, Fiers W et al. A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific alpha chain and a beta chain shared with the receptor for GM-CSF. Cell 1991; 66: 1175-1184.
26. Geijsen N, Koenderman L, Coffer PJ. Specificity in cytokine signal transduction: lessons learned from the IL-3/IL-5/GM-CSF receptor family. Cytokine Growth Factor Rev 2001; 12: 19-25.
27. Martinez-Moczygemba M, Huston DP. Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. J Allergy Clin Immunol 2003; 112: 653-665.
28. Takahashi S, Cui YH, Kojima T, Han YH, Zhou RL, Kamioka M et al. Family-based association study of markers on chromosome 22 in schizophrenia using African-American, European-American, and Chinese families. Am J Med Genet B Neuropsychiatr Genet 2003; 120: 11-17.
29. D'Andrea RJ, Harrison-Findik D, Butcher CM, Finnie J, Blumbergs P, Bartley P et al. Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice. J Clin Invest 1998; 102: 1951-1960.
30. Kendler KS, McGuire M, Gruenberg AM, O'Hare A, Spellman M, Walsh D. The Roscommon Family Study. III. Schizophrenia-related personality disorders in relatives. Arch Gen Psychiatry 1993; 50: 781-788.
31. Kendler KS, Myers JM, O'Neill FA, Martin R, Murphy B, MacLean CJ et al. Clinical features of schizophrenia and linkage to chromosomes 5q, 6p, 8p, and 10p in the Irish Study of High-Density Schizophrenia Families. Am J Psychiatry 2000; 157: 402-408.
32. Endicott J, Andreasen N, Spitzer RL. Family History Research Diagnostic Criteria. New York State Psychiatric Institute: New York, 1978.
33. Livak KJ. Allelic discrimination using fluorogenic probes and the 50 nuclease assay. Genet Anal 1999; 14: 143-149.
34. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy - Weinberg equilibrium. Am J Hum Genet 2005; 76: 887-893.
35. Martin ER, Monks SA, Warren LL, Kaplan NL. A test for linkage and association in general pedigrees: the pedigree disequilibrium test. Am J Hum Genet 2000; 67: 146-154.
36. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003; 25: 115-121.
37. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995; 12: 921-927.
38. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2004; 21: 263-265.
39. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 2225-2229.
40. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100: 9440-9445.
41. Yang J, Si T, Ling Y, Ruan Y, Han Y, Wang X et al. Association study between interleukin-1beta gene (IL-1beta) and schizophrenia. Life Sci 2003; 72: 3017-3021.
42. Yao JK, Sistilli CG, van Kammen DP. Membrane polyunsaturated fatty acids and CSF cytokines in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2003; 69: 429-436.
43. Mazzarello V, Cecchini A, Fenu G, Rassu M, Dessy LA, Lorettu L et al. Lymphocytes in schizophrenic patients under therapy: serological, morphological and cell subset findings. Ital J Anat Embryol 2004; 109: 177-188.
44. Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry 1993; 150: 1408-1410.
45. Ganguli R, Yang Z, Shurin G, Chengappa KN, Brar JS, Gubbi AV et al. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 1994; 51: 1-10.
46. Naudin J, Capo C, Giusano B, Mege JL, Azorin JM. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? Schizophr Res 1997; 26: 227-233.
47. Naudin J, Capo C, Giusano B, Mege JL, Azorin JM. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? Schizophr Res 1997; 26: 227-233.
48. Levitt P, Ebert P, Mirnics K, Nimgaonkar VL, Lewis DA. Making the case for a candidate vulnerability gene in schizophrenia: convergent evidence for regulator of G-protein signaling 4 (RGS4). Biol Psychiatry 2006; 60: 534-537.
49. Riley B, Kendler KS. Molecular genetic studies of schizophrenia. Eur J Hum Genet 2006; 14: 669-680.
50. Williams NM, O'Donovan MC, Owen MJ. Is the dysbindin gene (DTNBP1) a susceptibility gene for schizophrenia? Schizophr Bull 2005; 31: 800-805.
51. Tosato S, Dazzan P, Collier D. Association between the neuregulin 1 gene and schizophrenia: a systematic review. Schizophr Bull 2005; 31: 613-617.
52. Camargo LM, Collura V, Rain JC, Mizuguchi K, Hermjakob H, Kerrien S et al. Disrupted in Schizophrenia 1 Interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Mol Psychiatry 2007; 12: 74-86.
53. Norton N, Williams HJ, Owen MJ. An update on the genetics of schizophrenia. Curr Opin Psychiatry 2006; 19: 158-164.
54. Neale BM, Sham PC. The future of association studies: gene-based analysis and replication. Am J Hum Genet 2004; 75: 353-362.
55. Petryshen TL, Middleton FA, Kirby A, Aldinger KA, Purcell S, Tahl AR et al. Support for involvement of neuregulin 1 in schizophrenia pathophysiology. Mol Psychiatry 2005; 10: 366-374.
56. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004; 2: 13-35.
57. Halbreich U, Kahn LS. Hormonal aspects of schizophrenias: an overview. Psychoneuroendocrinology 2003; 28(Suppl 2): 1-16.
58. Shifman S, Bronstein M, Sternfeld M, Pisante-Shalom A, Lev-Lehman E, Weizman A et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002; 71: 1296-1302.
59. Tan EC, Chong SA, Wang H, Chew-Ping LE, Teo YY. Gender-specific association of insertion/deletion polymorphisms in the nogo gene and chronic schizophrenia. Brain Res Mol Brain Res 2005; 139: 212-216.
60. Thomson PA, Wray NR, Thomson AM, Dunbar DR, Grassie MA, Condie A et al. Sex-specific association between bipolar affective disorder in women and GPR50, an X-linked orphan G protein-coupled receptor. Mol Psychiatry 2005; 10: 470-478.
61. Salem JE, Kring AM. The role of gender differences in the reduction of etiologic heterogeneity in schizophrenia. Clin Psychol Rev 1998; 18: 795-819.
62. Czlonkowska A, Ciesielska A, Gromadzka G, Kurkowska-Jastrzebska I. Estrogen and cytokines production - the possible cause of gender differences in neurological diseases. Curr Pharm Des 2005; 11: 1017-1030.
63. Cahill L. Why sex matters for neuroscience. Nat Rev Neurosci 2006; 7: 477-484.
64. Bourdeau V, Deschenes J, Metivier R, Nagai Y, Nguyen D, Bretschneider N et al. Genome-wide identification of high-affinity estrogen response elements in human and mouse. Mol Endocrinol 2004; 18: 1411-1427.
65. Yang X, Schadt EE, Wang S, Wang H, Arnold AP, Ingram-Drake L et al. Tissue-specific expression and regulation of sexually dimorphic genes in mice. Genome Res 2006; 16: 995-1004.